Pharmaceuticals
Join Taipei City's Thriving Health Industry: Registration for "Win A Greater Health" Pitch Contest Starts Now!
TAIPEI, July 18, 2023 /PRNewswire/ -- The Taipei City Government's Department of Economic Development is taking proactive steps to attract international startups and foster collaboration with local businesses through its "Talent Exchange Program". In line with this initiative, they have establish...
2023-07-18 11:35
1968
SK Biopharmaceuticals Makes Big Bets to be 'Big Biotech'
SK Biopharmaceuticals CEO Donghoon Lee maps out its medium to long-term strategy at a press conference SK Biopharmaceuticals mobilizes its cutting-edge modality platforms of radiopharmaceutical therapy (RPT), targeted protein degradation (TPD), and cell and gene therapy (CGT) aligning with its v...
2023-07-18 09:00
1646
Antengene Announces First Patient Dosed in the Nivolumab Combination Portion of the Clinical Study Evaluating the ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors in the United States
- ATG-017 is an oral, potent and selective small molecule ERK1/2 inhibitor. Antengene has exclusive global rights to develop, commercialize, and manufacture ATG-017 - The combination portion of the ERASER study, the first-in-human (FIH) study of ATG-017, was designed to evaluate the safety/tole...
2023-07-18 08:30
2307
Qilian International Holding Group Ltd Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
JIUQUAN, China, July 17, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd (NASDAQ: QLI) ("Qilian" or the "Company"), aChina-based pharmaceutical and chemical products manufacturer, received notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq"), datedJuly ...
2023-07-17 22:30
5194
BIORCHESTRA Wins Grand Prize in 2023 Merck Advance Biotech Grant Program
* Recognition of outstanding in-vivo outcomes from a lead RNA program in CNS * Underpinned by proprietary IV-formulated, Brain-targeting Ribonucleic Acid Interference (RNAi) Nanomedicine (BTRiNTM) platform * BIORCHESTRA to receive in-kind products and services from Merck Group CAMBRIDGE, Mas...
2023-07-17 21:28
2025
ALZHEIMER'S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023
AMSTERDAM, July 17, 2023 /PRNewswire/ -- The data reported today by Eli Lilly from theTRAILBLAZER-ALZ 2 clinical trial of donanemab in early symptomatic Alzheimer's disease demonstrate an important advancement in Alzheimer's research and treatment. The full Phase 3 data was reported at the Alzh...
2023-07-17 21:15
2212
GeneQuantum and InxMed have reached a technology licensing collaboration, providing strong support for innovative ADC drug research and development
SUZHOU, China, July 17, 2023 /PRNewswire/ -- On July 14, 2023, GeneQuantum, a leading pioneer committed to innovative bioconjugation technology, and InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors...
2023-07-17 17:00
1474
Antengene Announces XPOVIO® Regulatory Approval in Hong Kong for the Treatment of Relapsed and/or Refractory Multiple Myeloma
* XPOVIO® (selinexor) is the first and only XPO1 inhibitor approved in Hong Kong * XPOVIO® has received regulatory approvals in 41 countries and regions includingthe United States, Israel, the United Kingdom, the European Union (the 27 member countries includingFrance and Italy), Canada, Norw...
2023-07-17 08:30
2705
Red Marrow Peptide-A Major Breakthrough in Human Health Engineering
BEIJING, July 14, 2023 /PRNewswire/ -- 1.8 g! This figure refers to the weight of red marrow which can be extracted from a 100 kg young yak growing in no-human zone ofQinghai and enjoys the reputation of "the key of cardiovascular health". It is called the most perfect "blood scavenger", ...
2023-07-14 12:51
2068
Menarini Silicon Biosystems announces the launch of its new CELLSEARCH® CTC test with the DLL3 biomarker for small cell lung cancer
This new CELLSEARCH Circulating Tumor Cell (CTC) test is now available as a Research Use Only (RUO) lab service inNorth America and Europe. It is currently intended for basic and pharmaceutical research and it is the latest example of how Menarini Silicon Biosystems continues its development of c...
2023-07-13 20:00
2997
Harbour BioMed Announces 2023 Interim Results Positive Profit Alert with the Enhancement of Value Driven by Innovation
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, July 13, 2023 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...
2023-07-13 18:11
4117
Sirnaomics to Present Latest Developments on Two Proprietary Delivery Platforms at Upcoming Industry Conferences
HONG KONG, Germantown, Md. and SUZHOU, China, July 12, 2023 /PRNewswire/ -- Sirnaomics Ltd.(the "Company", stock code: 2257, together with its subsidiaries, the"Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, hereby...
2023-07-12 20:45
2732
Raya Therapeutic announces early-stage R&D collaboration with argenx
MONTREAL, July 12, 2023 /PRNewswire/ -- Raya Therapeutic Inc., ("Raya") a mission-driven company focused on the treatment of neurodegenerative diseases, has entered into an early-stage R&D collaboration with argenx. The collaboration focuses on testing combinations of Raya's pipeline of targeted ...
2023-07-12 19:07
2235
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division
BOSTON, July 12, 2023 /PRNewswire/ -- Medicilon, a leading one-stop pharmaceutical preclinical R&D service platform CRO, recently appointed Dr.Liu Jian as the President of Drug Discovery Division. Medicilon recognizes the importance of drug discovery as the cornerstone of new drug innovation. Wit...
2023-07-12 18:46
2360
Biosyngen's First-in-class Cell Therapy BRG01 Receives FDA Fast Track Designation
SINGAPORE, July 12, 2023 /PRNewswire/ -- On July 6, 2023, Biosyngen received an official notification from the U.S. Food and Drug Administration (FDA) granting Fast Track Designation (FTD) to its revolutionary first-in-class immunotherapy, BRG01, for the treatment of relapsed/metastatic nasophary...
2023-07-12 13:38
3462
Creating the China-Singapore Translational Medicine Center - Biosyngen's pursuit to be a leading player in the CGT industry globally hits new milestone.
SINGAPORE, July 12, 2023 /PRNewswire/ -- This is a model of cooperation between Singapore and China, more importantly, working jointly in the area of research and development. Through this initiative, China Singapore Knowledge City paths the way to attract both local and overseas therapeutic asse...
2023-07-12 10:32
3230
Sciwind Biosciences Announces Publication of Discovery, Preclinical, and Phase 1 Clinical Trial Results of Ecnoglutide (XW003) in Molecular Metabolism
HANGZHOU, China and SAN FRANCISCO, July 12, 2023 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced the publication of discovery, preclinical characteriza...
2023-07-12 10:00
2509
GI Dynamics Announces Company Rebrand as Morphic Medical® Reintroducing Flagship Product as RESET®
BOSTON, July 11, 2023 /PRNewswire/ -- GI Dynamics, creator of the world's first medical device designed to target the underlying cause of type 2 diabetes, is proud to announce its rebrand to Morphic Medical and the introduction of RESET, formally known as EndoBarrier®. This transformative shift r...
2023-07-12 07:12
2212
Doer Biologics Announces License Agreement with BioNTech
HANGZHOU, China, July 10, 2023 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announced that it has entered into a license agreement with BioNTech SE (Nasdaq...
2023-07-11 11:49
1944
Race executes global license agreement with City of Hope to access FTO IP
* Race executes worldwide license agreement with City of Hope, one of the largest cancer research and treatment organisations inthe United States. * Under the agreement, Race will exclusively secure rights to a City of Hope patent application and associated know-how identifying that bisantrene...
2023-07-11 07:30
2415
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 298 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 294 media titles]
2024-11-26 13:00TAILG's First Flagship Store in Indonesia Grandly Opens
[Picked up by 283 media titles]
2024-11-22 21:59
MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 278 media titles]
2024-11-25 10:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9306
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
9289
